UNIVERSITATSKLINIKUM BONN

Their core work

Universitätsklinikum Bonn (UKB) is a major German university hospital that combines clinical care with translational biomedical research. Their core strength lies in neuroscience and neurodegenerative disease research — particularly Alzheimer's, brain simulation, and neuroinformatics — alongside clinical work in rare diseases, liver pathology, ophthalmology, and infectious disease preparedness. They bridge laboratory science and patient outcomes, contributing disease models, clinical trial infrastructure, and patient cohorts to large European research consortia. Their involvement in the Human Brain Project positions them at the intersection of neuroscience and high-performance computing.

What they specialise in

How they've shifted over time

In their early H2020 period (2014–2018), UKB focused broadly on autoimmune disease, infectious disease preparedness (virus archives, Zika), integrated care for chronic patients, and liver pathology — a classic university hospital research profile spread across clinical domains. From 2018 onward, their work concentrated notably on neuroscience and brain research through the Human Brain Project, rare disease diagnostics via European Reference Networks, and ophthalmology (MACUSTAR). The shift signals a strategic deepening into computational neuroscience and translational clinical research for diseases with high unmet medical need.

UKB is consolidating around neuroscience, neuroinflammation, and data-driven rare disease diagnostics — future partners should expect strength in these areas rather than broad clinical coverage.

How they like to work

UKB operates primarily as an active partner (35 of 42 projects), joining large consortia where they contribute clinical expertise, patient cohorts, and disease-specific knowledge. They coordinate selectively — 7 projects, typically in areas of deep specialization like neuroinflammation (PHAGO) and ophthalmology (MACUSTAR). With 506 unique partners across 44 countries, they are a well-connected hub in European health research, comfortable in both massive flagship projects (Human Brain Project) and focused clinical networks.

UKB has worked with 506 distinct consortium partners across 44 countries, making them one of the most broadly networked university hospitals in H2020 health research. Their reach extends well beyond the EU into global partnerships, particularly through infectious disease and rare disease networks.

What sets them apart

UKB stands out by combining a world-class clinical hospital setting with deep computational neuroscience involvement through the Human Brain Project — a rare mix among university hospitals. Their coordination of MACUSTAR (EUR 3.8M for macular degeneration endpoints) demonstrates their ability to lead large clinical validation studies, not just contribute patient data. For consortium builders, UKB offers the dual advantage of clinical trial infrastructure and disease biology expertise, particularly in neurodegeneration and ophthalmology.

Highlights from their portfolio

• MACUSTAR
  UKB's largest grant (EUR 3.8M) as coordinator, developing and validating clinical endpoints for age-related macular degeneration — a flagship translational ophthalmology project.
• PHAGO
  Coordinated a EUR 1.75M project targeting TREM2 and CD33 microglia pathways in Alzheimer's disease, positioning UKB at the forefront of neuroinflammation research.
• HBP SGA1
  Participation in the Human Brain Project — one of the EU's largest flagship initiatives — linking UKB to the intersection of neuroscience and high-performance computing.